Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE: Qutenza Safety in Diabetic Peripheral Neuropathy
NCT01478607Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of capsaicin 8% patch in diabetic peripheral neuropathy (DPN), sponsored by Astellas Pharma. Started Nov 2011; status: completed.
02
Drugs
capsaicin 8% patch
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01478607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478607.